Company intelligence / Profile preview

CLAIRIgene

Durham, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

CLAIRIgene has demonstrated promising preclinical activity in modulating key genetic drivers of neurodegenerative diseases. Their lead program, CLRI-002, targets APOE4 and has shown reduction of pathological p-Tau in Alzheimer’s models with little to no toxicity. The CLRI-001 program targeting SNCA is licensed to Seelos Therapeutics and has reversed disease-related phenotypes in patient-derived neurons

Therapeutic areas: Neurology
Modalities: Gene therapyEpigenome editingAAV-based gene therapyLentiviral vector-based gene therapyCRISPR-dCas9-based epigenome editing
Industry: Biotech

Drug pipeline

1 asset

AAV-CRISPR-KRAB-MeCP2(TRD)

Preclinical

Partnerships

Seelos Therapeutics (licensing/partnership on PD therapeutic)Duke Viral Vector CoreDuke Translational Brain Sciences, Dept. of Neurology

Beyond the preview

Go deeper on CLAIRIgene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLAIRIgene.

Explore the full profile